The effect of analgesia with omnopon and dexketoprofen on the endocytic activity of phagocytes of different localization on the surgical tumor resection model

N. Khranovska, O. Skachkova, R. Sydor, L. Skivka
National cancer institute, Kyiv; National cancer institute, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv


We aimed to compare the effect of anesthesia with opioid analgesics omnopon and non-selective COX-2 inhibitor dexketoprofen on the endocytic activity of phagocytes of different localization sites on the model of surgical tumor removal. The study used 50 C57/black mice, which were transplanted with Lewis lung carcinoma in the hind paw pad. After 22 days the tumor paw was amputated. Analgesics (omnopon 10 mg/kg, dexketoprofen – 20 mg/kg) was administered 30 minutes before the operation and once per day for 3 days after surgery. Assessment of endocytic activity of phagocytes was performed by flow cytometry before the surgery, at days 1 and 3 after the surgery. It was found that dexketoprofen analgesia maintain the endocytic activity of blood and spleen phagocytes in the postoperative period. At day 3 postsurgery in dexketoprofen-
treated animals phagocytic activities of blood and spleen granulocytes were higher compared to the group receiving opioid analgesia by 70% and 86% respectively. Phagocytic indices of blood and spleen monocytes were also 2 times higher at dexketoprofen-treated mice. Thus, dexketoprofen analgesia maintains the activity of blood and spleen phagocytes in mice after the surgical tumor removal at a much higher level as compared with the omnopon analgesia.


phagocytic activity, perioperative analgesia, cyclooxygenase-2 inhibitors, opioid drugs

Full Text:



Das J, Kumar S, Khanna S, Mehta Y. Are we causing the recurrence-impact of perioperative period on long-term cancer prognosis: Review of current evidence and practice. J Anaesthesiol Clin Pharmacol. 2014;30(2):153-9.

Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40(9):793-808.

Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle. 2009;8(20):3267-73.

Maskrey BH, Megson IL, Whitfield PD, Rossi AG. Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arterioscler Thromb Vasc Biol. 2011;31(5):1001-6.

Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol. 2010;10(6):427-39.

Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659(1-2):15-30.

Meserve JR, Kaye AD, Prabhakar A, Urman RD. The role of analgesics in cancer propagation. Best Pract Res Clin Anaesthesiol. 2014 ;28(2):139-51.

Kaye AD, Patel N, Bueno FR, Hymel B, Vadivelu N et al. Effect of opiates, anesthetic techniques, and other perioperative factors on surgical cancer patients. Ochsner J. 2014;14(2):216-28.

Yiannakopoulou E. Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention. Cell Oncol (Dordr). 2014;37(3):167-78.

Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17(2):55-67.

Kurosawa S. Anesthetics, immune cells, and immune responses. J Anesth. 2008;22(3):263-77.

Xie R, Gao C, Li W, Zhu J, Novakovic V, et al. Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells. Blood. 2012 8;119(10):2325-34.

Bronte V. The spleen in local and systemic regulation of immunity Immunity. 20130;39(5):806-18.

Stefano GB, Kream RM, Mantione KJ, Sheehan M, Cadet P, Zhu W, Bilfinger TV, Esch T. Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology]. Semin Cancer Biol. 2008 ;18(3):199-210. German.

Menzebach A, Hirsch J, Nöst R, Mogk M, Hempelmann G, Welters ID. [Morphine inhibits complement receptor expression, phagocytosis and oxidative burst by a nitric oxide-dependent mechanism. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004;39(4):204-11.

Fedorchuk OG, Pyaskovskaya OM, Skivka LM, Gorbik GV, Trompak OO, Solyanik GI. Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: relations with tumor derived VEGF. Cytokine. 2012 Jan;57(1):81-8.

Shirzad H, Shahrani M, Rafieian-Kopaei M. Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes in vivo. Int Immunopharmacol. 2009 ;9(7-8):968-70.

Tanja C. The fundamental role of mechanical properties in the progression of cancer disease and inflammation. Reports on Progress in Physics. 2014;77(7):121-126.

Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood. 2016;127(18):2173-81.

Medeiros A, Peres-Buzalaf C, Fortino Verdan F, Serezani CH. Prostaglandin E2 and the suppression of phagocyte innate immune responses in different organs. Mediators Inflamm. 2012;2012:327568.



  • There are currently no refbacks.

Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).